Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer
Presented by: Bayer Dendreon and Janssen Oncology Los Padres
Guest Speakers:
Dr. Edwin Morales - Urology Specialist, San Antonio
Dr. Michael Liss - Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
Dr. Vijay K. Gunuganti - Medical Oncologist at Texas Oncology
Moderator: Dr. Juan A. Reyna - Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
View the full video by clicking on the image below; or scroll down to access links to short video segments about specific content presented at the event.
VIDEO
Click any link listed below to go straight to that segment of the video:
0:01 - Introduction - Terri Likowski, Us TOO Program Director - Support Group Services
0:50 - Johnny Staha - Support Group Leader - San Antonio, TX
1:07 - Chuck Strand - CEO, Us TOO International
3:04 - Intro to Dr. Juan A. Reyna
4:44 - Dr. Juan A. Reyna - Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health
10:00 - Intro to Dr. Edwin Morales
10:56 - Dr. Edwin Morales - Urology Specialist, San Antonio
11:01 - Prostate Cancer Overview, Definitions, Terms
11:52 - Biochemical Recurrence
14:29 - (Non) Metastatic Castrate Resistant Prostate Cancer
17:52 - The Androgen Receptor Axis
20:47 - Androgen Deprivation Therapy
21:17 - After ADT
23:00 - Options for Rising PSA After CAB/AAW
23:44 - Asymptomatic Non - Metastatic Castrate Resistant Prostate Cancer
26:36 - Options for Asymptomatic Non - Metastatic Castrate Resistant Prostate Cancer
32:16 - The "New" Natural History of Prostate Cancer
33:45 - Intro to Dr. Vijay Gunuganti
34:26 - Dr. Vijay Gunuganti - Oncologist at Texas Oncology
35:03 - Lifetime Probability of Developing Cancer
36:07 - Multidisciplinary Team Approach to PCa Management
37:02 - Treatment for CRPC
37:24 - Early Metastatic Prostate Cancer or Hormone Sensitive Prostate Cancer
37:58 - The CHAARTED Hypotheses
38:45 - LATITUDE Trial
39:19 - STAMPEDE Trial
39:33 - Results of Androgen Removal
40:17 - Castrate Resistant Metastatic Prostate Cancer or Hormone Refractory Prostate Cancer
40:59 - Enzalutamide
41:47 - Abiraterone
42:28 - Metastatic Bone Lesions
43:39 - Xofigo
44:10 - Phase III ALSYMPCA Study Design: Patient Eligibility
45:38 - Treatment of Symptomatic, Hormone Refractory Metastatic Disease with Chemotherapy
46:52 - Side Effects of Chemotherapy
48:07 - Currently Approved Therapy for Advanced Prostate Cancer
49:48 - Intro to Dr. Michael Liss
50:52 - Dr. Michael Liss - Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
51:56 - Screening, PSA Testing, At - Risk Groups
54:35 - African American Men, Family History
55:18 - Individualized Risk Assessment Approach, Shared Decision Making
57:20 - Hereditary Prostate Cancer
58:43 - BRCA
58:54 - Genetics - Risk Using SNPs
59:50 - Functional vs. Non - Functional Genes
1:00:31 - Prostate Genetic Score
1:01:04 - Genomics for Treatment Decisions
1:04:56 - Future of Clinical Trials
1:06:11 - Prostate Imaging - MRI
1:08:29 - Software Detection Technologies, Restricted Spectrum Imaging
1:09:08 - PET/CT Imaging
1:10:32 - Oligometastatic Prostate Cancer Clinical Trials
1:12:35 - Q&A
